Lilly Sees Path for Zepbound’s Label Expansion With Phase III Sleep Apnea Win

Lilly Sees Path for Zepbound’s Label Expansion With Phase III Sleep Apnea Win

Source: 
BioSpace
snippet: 

Eli Lilly on Friday unveiled detailed findings from the Phase III SURMOUNT-OSA program, showing that its blockbuster weight-loss drug Zepbound (tirzepatide) could significantly improve disease severity in patients with moderate-to-severe obstructive sleep apnea and obesity.